drugset / Trial / NCT06210971
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This single-arm trial will explore the efficacy and safety of long-course neoadjuvant chemoradiation with liposomal irinotecan and capecitabine guided by UGT1A1 status in patients with locally advanced rectal cancer.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2026-02-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 625 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 50 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 70 mg/m2 | — |